Mesa lab testing new leg wound care products | | eastvalleytribune.com
BioLab Holdings, a Mesa medical manufacturer, has initiated clinical trials for an FDA-approved amniotic membrane tissue to treat difficult-to-heal venous leg ulcers. The trials aim to assess the product's efficacy and expand treatment options for chronic wounds, which affect 2.5% of the U.S. population and 10.5 million Medicare beneficiaries.
Highlighted Terms
Related News
Mesa lab testing new leg wound care products | | eastvalleytribune.com
BioLab Holdings, a Mesa medical manufacturer, has initiated clinical trials for an FDA-approved amniotic membrane tissue to treat difficult-to-heal venous leg ulcers. The trials aim to assess the product's efficacy and expand treatment options for chronic wounds, which affect 2.5% of the U.S. population and 10.5 million Medicare beneficiaries.